公开(公告)号：US5945413A

公开(公告)日：1999-08-31

申请号：US724563

申请日：1996-09-30

申请人： Roger Dennis Tung ,  Francesco Gerald Salituro ,  David D. Deininger ,  Govinda Rao Bhisetti ,  Christopher Todd Baker ,  Andrew Spaltenstein

发明人： Roger Dennis Tung ,  Francesco Gerald Salituro ,  David D. Deininger ,  Govinda Rao Bhisetti ,  Christopher Todd Baker ,  Andrew Spaltenstein

IPC分类号： C07D207/26 ,  C07D207/27 ,  C07D233/36 ,  C07D265/32 ,  C07D265/34 ,  C07D285/10 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D491/10 ,  A61K41/315 ,  A61K31/40 ,  A61K31/41 ,  A61K31/415 ,  A61K31/425 ,  A61K31/43 ,  A61K31/44 ,  A61K31/47

CPC分类号： C07D207/27 ,  C07D233/36 ,  C07D265/32 ,  C07D265/34 ,  C07D285/10 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D491/10

摘要： This invention relates to a novel class of compounds that are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting aspartyl protease activity and methods for treating viral infections using the compounds and compositions of this invention.

摘要翻译： 本发明涉及一类新颖的天冬氨酰蛋白酶抑制剂。 在一个实施方案中，本发明涉及以特异性结构和物理化学特征为特征的新型天冬氨酰蛋白酶抑制剂。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此可有利地用作针对HIV-1和HIV-2病毒的抗病毒剂。 本发明还涉及使用本发明的化合物和组合物来抑制天冬氨酰蛋白酶活性的方法和治疗病毒感染的方法。

公开(公告)号：US06838474B2

公开(公告)日：2005-01-04

申请号：US10370171

申请日：2003-02-19

申请人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

发明人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

IPC分类号： A61K31/18 ,  A61K31/215 ,  A61K31/265 ,  A61K31/27 ,  A61K31/34 ,  A61K31/341 ,  A61K31/4025 ,  A61K31/496 ,  A61K31/66 ,  A61K31/661 ,  A61K31/664 ,  A61K31/7048 ,  A61K45/00 ,  A61P31/12 ,  A61P31/18 ,  A61P43/00 ,  C07C311/15 ,  C07C311/18 ,  C07C311/37 ,  C07D277/30 ,  C07D307/20 ,  C07D405/12 ,  C07D407/12 ,  C07D417/12 ,  C07F9/655 ,  C07F9/6584 ,  C07H15/04 ,  C07H15/26 ,  A61K31/427

CPC分类号： C07D405/12 ,  C07C311/18 ,  C07D307/20 ,  C07F9/65515 ,  C07F9/65844 ,  C07H15/04

摘要： The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

公开(公告)号：US20100124543A1

公开(公告)日：2010-05-20

申请号：US12504243

申请日：2009-07-16

申请人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

发明人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

IPC分类号： A61K31/4025 ,  C07D307/20 ,  C07D405/12 ,  C07C69/96 ,  C07C271/20 ,  A61P31/12 ,  A61K31/341 ,  A61K31/496 ,  A61K31/443 ,  A61K31/4178 ,  A61K31/27 ,  A61K31/265 ,  A61K31/7072 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/715 ,  A61K31/52 ,  A61K31/551 ,  A61K38/20 ,  A61K38/19 ,  A61K38/21

CPC分类号： C07D405/12 ,  C07C311/18 ,  C07D307/20 ,  C07F9/65515 ,  C07F9/65844 ,  C07H15/04

摘要： The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

摘要翻译： 本发明涉及作为天冬氨酰蛋白酶抑制剂的一类磺酰胺的前药。 在一个实施方案中，本发明涉及HIV天冬氨酰蛋白酶抑制剂的新一类前药，其特征在于有利的水溶性，高口服生物利用度和活性成分的体内易生成。 本发明还涉及包含这些前药的药物组合物。 本发明的前药和药物组合物特别适用于降低药丸负担并增加患者依从性。 本发明还涉及用这些前药和药物组合物治疗哺乳动物的方法。

公开(公告)号：US06559137B1

公开(公告)日：2003-05-06

申请号：US09602494

申请日：2000-06-23

申请人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

发明人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

IPC分类号： A61K3116

CPC分类号： C07D405/12 ,  C07C311/18 ,  C07D307/20 ,  C07F9/65515 ,  C07F9/65844 ,  C07H15/04

摘要： The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

公开(公告)号：US07592368B2

公开(公告)日：2009-09-22

申请号：US10958223

申请日：2004-10-04

申请人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

发明人： Roger Dennis Tung ,  Michael Robin Hale ,  Christopher Todd Baker ,  Eric Steven Furfine ,  Istvan Kaldor ,  Wieslaw Mieczylaw Kazmierski ,  Andrew Spaltenstein

IPC分类号： A61K31/34 ,  C07D307/02

CPC分类号： C07D405/12 ,  C07C311/18 ,  C07D307/20 ,  C07F9/65515 ,  C07F9/65844 ,  C07H15/04

摘要： The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

摘要翻译： 本发明涉及作为天冬氨酰蛋白酶抑制剂的一类磺酰胺的前药。 在一个实施方案中，本发明涉及HIV天冬氨酰蛋白酶抑制剂的新一类前药，其特征在于有利的水溶性，高口服生物利用度和活性成分的体内易生成。 本发明还涉及包含这些前药的药物组合物。 本发明的前药和药物组合物特别适用于降低药丸负担并增加患者依从性。 本发明还涉及用这些前药和药物组合物治疗哺乳动物的方法。

公开(公告)号：US20080194523A1

公开(公告)日：2008-08-14

申请号：US11997779

申请日：2006-07-28

申请人： Brian A. Johns ,  Andrew Spaltenstein

发明人： Brian A. Johns ,  Andrew Spaltenstein

IPC分类号： A61K31/675 ,  C07F9/02 ,  A61P31/12

CPC分类号： C07F9/6561 ,  C07D471/04

摘要： The present invention features compounds that are HIV integrase inhibitors and may be useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

摘要翻译： 本发明具有作为HIV整合酶抑制剂的化合物，并且可用于抑制HIV复制，HIV的感染的预防和/或治疗以及AIDS和/或ARC的治疗。

公开(公告)号：US20060172936A1

公开(公告)日：2006-08-03

申请号：US11212045

申请日：2005-08-25

申请人： Michael Hale ,  Clarence Andrews ,  Eric Furfine ,  Ronald Sherrill ,  Andrew Spaltenstein ,  Gregory Lowen

发明人： Michael Hale ,  Clarence Andrews ,  Eric Furfine ,  Ronald Sherrill ,  Andrew Spaltenstein ,  Gregory Lowen

IPC分类号： A61K38/17 ,  A61K31/70 ,  A61K31/325

CPC分类号： C07D213/30 ,  C07C311/48 ,  C07C311/49 ,  C07C2601/08 ,  C07C2601/14 ,  C07D215/48 ,  C07D235/06 ,  C07D235/26 ,  C07D235/30 ,  C07D235/32 ,  C07D241/42 ,  C07D243/04 ,  C07D265/02 ,  C07D277/30 ,  C07D307/20 ,  C07D309/06 ,  C07D309/12 ,  C07D309/22 ,  C07D319/06 ,  C07D401/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/06 ,  C07D417/12 ,  C07D493/04 ,  C07F9/6561

摘要： The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods For inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

摘要翻译： 本发明涉及一类新型的磺酰胺，它们是天冬氨酰蛋白酶抑制剂。 在一个实施方案中，本发明涉及以特定结构和物理化学特征为特征的新型HIV天冬氨酰蛋白酶抑制剂。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此可有利地用作针对HIV-1和HIV-2病毒的抗病毒剂。 本发明还涉及使用本发明化合物抑制HIV天冬氨酰蛋白酶活性的方法和用于筛选抗HIV活性化合物的方法。

公开(公告)号：US20090042973A1

公开(公告)日：2009-02-12

申请号：US12217517

申请日：2008-07-02

申请人： Michael R. Hale ,  Christopher T. Baker ,  Timothy A. Stammers ,  Ronald George Sherrill ,  Andrew Spaltenstein ,  Eric Steven Furfine ,  Francois Maltais ,  Clarence Webster Andrews, III ,  John Franklin Miller ,  Vicente Samano

发明人： Michael R. Hale ,  Christopher T. Baker ,  Timothy A. Stammers ,  Ronald George Sherrill ,  Andrew Spaltenstein ,  Eric Steven Furfine ,  Francois Maltais ,  Clarence Webster Andrews, III ,  John Franklin Miller ,  Vicente Samano

IPC分类号： A61K31/343 ,  C07C255/03 ,  C07D307/78 ,  A61K31/352 ,  A61P31/18 ,  C07D319/16 ,  A61K31/277

CPC分类号： C07C311/19 ,  C07C311/29 ,  C07C311/42 ,  C07C311/46 ,  C07C317/18 ,  C07D307/20 ,  C07D319/06 ,  C07D493/04 ,  C07F9/6561

摘要： The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

公开(公告)号：US07442718B2

公开(公告)日：2008-10-28

申请号：US10613650

申请日：2003-07-02

申请人： Michael R Hale ,  Christopher T Baker ,  Timothy A Stammers ,  Ronald G Sherrill ,  Andrew Spaltenstein ,  Eric S Furfine ,  Francois Maltais ,  Clarence W Andrews, III ,  John F Miller ,  Vicente Samano

发明人： Michael R Hale ,  Christopher T Baker ,  Timothy A Stammers ,  Ronald G Sherrill ,  Andrew Spaltenstein ,  Eric S Furfine ,  Francois Maltais ,  Clarence W Andrews, III ,  John F Miller ,  Vicente Samano

IPC分类号： A61K31/357 ,  C07D317/46

CPC分类号： C07C311/19 ,  C07C311/29 ,  C07C311/42 ,  C07C311/46 ,  C07C317/18 ,  C07D307/20 ,  C07D319/06 ,  C07D493/04 ,  C07F9/6561

摘要： The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

摘要翻译： 本发明涉及一类新型的磺酰胺，它们是天冬氨酰蛋白酶抑制剂。 在一个实施方案中，本发明涉及以特定结构和物理化学特征为特征的新型HIV天冬氨酰蛋白酶抑制剂。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此可有利地用作针对HIV-1和HIV-2病毒的抗病毒剂。 本发明还涉及使用本发明化合物抑制HIV天冬氨酰蛋白酶活性的方法和用于筛选抗HIV活性化合物的方法。

公开(公告)号：US20080234231A1

公开(公告)日：2008-09-25

申请号：US11997795

申请日：2006-07-28

申请人： Brian A. Johns ,  Andrew Spaltenstein

发明人： Brian A. Johns ,  Andrew Spaltenstein

IPC分类号： A61K31/675 ,  A61P31/12 ,  C07F9/58

CPC分类号： C07D471/04

摘要： The present invention features compounds that are HIV integrase inhibitors and may be useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.